Champions Oncology reports record FY2022 revenue $49.1M (+20%); guides for 20% growth in FY2023

CHAMPIONS ONCOLOGY, INC.

Record annual revenue $49.1M, up 20% YoY; Q4 revenue $12.9M, up 22% from $10.6M.
FY2022 gross margin improved to 52% (from 48%); adjusted EBITDA $3.1M vs $2.1M.
Operating income $607K for FY2022; cash $9.0M, no debt.
Guidance: projects another year of top-line growth of ~20% for FY2023.
CEO notes expanding ex-vivo services and computational discovery tools moving to preclinical development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.